Cite
HARVARD Citation
Gong, J. et al. (2016). Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC cancer. 16 (1), pp. 1-9. [Online].